Aplastic Anaemia

Top drugs studied for this disease

All Approvals Safety alerts Label changes Trial results Research Guidance Withdrawals

EMA approval · 2026-02-26
EMA Authorised: Revolade (eltrombopag) — Novartis Europharm Limited
The EMA authorized Revolade (eltrombopag). It covers idiopathic thrombocytopenic purpura and aplastic anaemia.